# Roshan Health Hub — Session Continuation Handoff
**Snapshot date:** 2026-11-03 (UTC)  
**Repository:** `crauch2088-source/roshan-health-hub`  
**Default branch:** `main`  
**Snapshot main SHA:** `d2cb1e068e4bcf78e20968c77f255b160f77d9f2`

> This document records the verified repository/PR state at the end of the 2026-11-03 prescribing-safety work session. Re-fetch live state before acting; PRs, checks, deployments and branches may have changed.

## 1. Operating instructions

- Continue implementation, not just planning or status narration. The owner has already granted broad authorization for appropriate project work.
- Treat `docs/MASTER_PLAN.md` as the cumulative roadmap/source of truth. Spec Kit owns feature-level specification, plan, tasks and contracts; it does not replace the Master Plan.
- Read current `README.md`, `docs/MASTER_PLAN.md`, `docs/PLUGIN_TOOLING_MAP.md`, `docs/DB_MIGRATION_RECONCILIATION.md`, `docs/SECURITY_PR_REVIEW.md`, and `specs/056-evidence-based-prescribing/` before substantive implementation.
- Follow repository quota-safe execution policy: one atomic commit per logical task; avoid redundant CI runs; docs-only work must not trigger frontend deployments; respect Vercel free quota; squash-merge; never rewrite published history or force-push.
- Use TDD for behavior changes. Do not claim tests passed unless an exact run on the relevant SHA is confirmed.
- QA first. Do not apply candidate migrations or make production data/schema changes as part of this work without the applicable release gates. Never add synthetic patient/financial records to Production.
- The owner is a GP and prefers concise, useful Arabic progress reports. Medical decision support must be evidence-based, source-cited, and clinically reviewed.

## 2. Current repository and deployment snapshot

- Last confirmed `main` commit: `d2cb1e068e4bcf78e20968c77f255b160f77d9f2` — “docs(spec): reconcile Phase 53 plan and release gates”.
- The main commit's combined status currently reports a failed Vercel context pointing to `build-rate-limit`. This is a deployment quota limitation, not evidence of an application build/test failure.
- The workflow-runs lookup returned no PR-triggered workflow runs for this main SHA. Do **not** describe main Actions as green based on that response.
- Production URL: https://roshan-health-hub.vercel.app/
- Production Supabase: `jewzonxplxhogqrnhosl`
- QA Supabase: `hopfohcnrtbiqjkgeukz`
- Production database writes remain out of scope for this handoff.

## 3. Live PR state at snapshot time

All four PRs below were re-fetched on 2026-11-03. All were still open and unmerged.

| PR | Purpose | Head SHA | Base SHA | State | Exact-head Actions evidence | Vercel |
|---|---|---|---|---|---|---|
| [#185](https://github.com/crauch2088-source/roshan-health-hub/pull/185) | Evidence-based prescribing Spec Kit documentation | `4c07262097870013fec02a68262f6a327d269f51` | `d2cb1e068e4bcf78e20968c77f255b160f77d9f2` | Open, not draft, mergeable; 11 files, +860 | CI run 1598 and Spec Kit validation run 27 completed successfully | Failed with `build-rate-limit` |
| [#183](https://github.com/crauch2088-source/roshan-health-hub/pull/183) | Require explicit prescription administration route | `60ee5208b3927a86b3c4b3649f366667a8b657d8` | `f648be5e6499205c90b79129628ca9ccdc4b42b8` | Open, not draft, mergeable; 3 files, +35/-4 | CI 1578, insurance UI validation 406, prescription atomicity 498, privileged role guard 501, insurance integrity 501 all succeeded | Failed with `build-rate-limit` |
| [#125](https://github.com/crauch2088-source/roshan-health-hub/pull/125) | Usable custom prescription fields and safety cues | `27537db4d22833757998c9e6d250eb2c9aff4cd0` | `05d065415d32bddea56ad6a6cc0fbdefd5fcd9f3` | Open, not draft, mergeable; 5 files, +207/-89 | CI 1488, prescription atomicity 445, privileged role guard 448, insurance integrity 448, insurance UI validation 370 all succeeded | Successful status observed |
| [#179](https://github.com/crauch2088-source/roshan-health-hub/pull/179) | Phase 53 safe saved-prescription printing | `b2e4f67334f7f49fc4fa86ae8e06614b4f95b263` | `d2cb1e068e4bcf78e20968c77f255b160f77d9f2` | Open, Draft, mergeable; 15 files, +719/-126 | Eight exact-head workflows completed successfully, including CI 1596 and PostgreSQL 17 Phase 48 workflow 47 | Successful status observed |

**Important corrections to earlier notes:**
- PR #185 is no longer Draft. Its latest known head is `4c072620...`, not the older `69a0479...`; it now reports 11 files and 860 additions.
- PR #179's latest known head is `b2e4f673...`, not the older `8389b949...`.
- PR #183 and #125 still target older base SHAs. Do not merge them without reconciling with current `main`.
- “Mergeable” is GitHub metadata, not proof that overlapping clinical changes are safe to merge.

## 4. Prescribing-related source audit already recorded in Master Plan

The existing section “Prescription UX and medication safety review — 2026-11-03” in `docs/MASTER_PLAN.md` records the earlier source audit. Its verified findings include:

1. `src/lib/prescription-draft.ts` previously inferred `oral` route for tablet/capsule/syrup/suspension forms. PR #183 removes that unsafe inference and requires explicit route selection.
2. Main's prescription draft validation did not require dosage form or route; PR #125 adds custom-field usability/completeness changes but overlaps shared prescription files.
3. The “Custom” select choices did not provide corresponding free-text inputs in the inspected main source.
4. Medicine catalogue maintenance did not populate all structured fields used by prescription selection/search.
5. Pharmacy queue summaries omitted persisted dosage form, route and instructions.
6. Pediatric UI cues asked clinicians to verify visit weight and maximum daily dose; they did not calculate a dose.

Treat the Master Plan audit as prior source evidence, not proof that the current live branches or main still have identical code. Re-open the exact current files and PR patches before modifying them.

## 5. Evidence-based prescribing feature (Spec 056)

PR #185 contains the feature specification and planning artifacts for evidence-based prescribing decision support. The design requires:

- Product/formulation-specific route compatibility; dosage form or drug name alone must not infer a route, dose or frequency.
- A confirmed structured indication before matching a treatment protocol.
- Encounter-linked weight and timestamped vitals; no silent reuse of historical weight.
- A deterministic, versioned, explainable rules engine.
- Explicit distinction between `mg/kg/dose` and `mg/kg/day`, maximum doses, units, rounding, concentration, age/gestational limits and required inputs.
- Withholding a recommendation when required clinical data are missing.
- Governed alert severity and controls against alert fatigue.
- A traceable source, version, population, indication, review/expiry date, tests and clinical/pharmacy approval for every active rule.
- AI must not invent doses, interaction severity or unsupported clinical facts.

**Critical status:** documentation is not implementation. No validated regimen set or interaction knowledge base was approved/activated at this snapshot.

## 6. QA database facts from the previous read-only inspection

The last documented QA inspection found:

- `public.medicines` contained zero rows; there was no real formulary cohort available to seed or validate.
- Weight already exists in `vitals`, linked to `visit_id`; do not add a patient-master weight as a substitute for encounter measurements.
- `patients.allergies` and `patients.chronic_conditions` were free-text fields; a structured allergy/adverse-reaction and interaction knowledge model was not identified in that inspection.
- `prescription_items` already includes fields such as `medicine_id`, `medication_name`, `dose`, `frequency`, `duration`, `dosage_form`, and `route`.
- Patient creation uses `create_patient_atomic`.
- Visit creation and consultation invoice creation were separate operations in the inspected UI flow. Do not combine or reorder them without analyzing transactionality, permissions and billing effects.

These are **previously observed QA facts**, not a fresh database query in this documentation-only session. Re-check QA read-only before implementation.

## 7. Clinical references and evidence limits

Prior research identified these starting points; verify current primary-source versions before encoding any rules:

- WHO AWaRe Antibiotic Book (2022).
- WHO recommendations for serious bacterial infections in infants 0–59 days (2024).
- WHO meningitis diagnosis, treatment and care guideline (2025).
- NICE NG5 Medicines Optimisation.
- NICE CG183 Drug Allergy.
- FDA Clinical Decision Support Software Guidance (January 2026).
- HL7 FHIR R5 MedicationKnowledge and FHIR Dosage.
- Sudan National Essential Medicines List (2019) — do not assume it is the latest.
- Sudan Federal Ministry of Health Standard Treatment Guidelines (2014) surfaced in prior research, but current validity and primary-document access were not established.
- A 2025 Sudan primary-care antimicrobial prescribing study is stewardship context, not a dosing guideline.

No Sudan-specific regimen should be represented as current national policy until the current official source is located and reviewed. Require GP/pharmacist review before activating clinical rules.

## 8. Next actions for the next session

### A. Refresh state before any write
1. Fetch current `main` SHA and latest repository docs.
2. Re-fetch PRs #185, #183, #125, #179 and their exact-head workflow/status evidence.
3. Compare each branch with current `main`; identify duplicate commits, divergence and overlapping file changes.
4. Inspect Vercel quota status without attempting a bypass or paid upgrade.
5. Re-run one batched, read-only QA schema/formulary/permission inspection only if it materially changes the next implementation decision.

### B. Reconcile prescription branches
1. Inspect exact patches for shared files, especially `PrescriptionTab.tsx`, `medical.ts`, `prescription-draft.ts`, print model and relevant tests.
2. Preserve the safety fix from #183 and useful custom-field behavior from #125.
3. Integrate printing from #179 only after reviewing print content, privacy, patient identity, branch, saved-prescription state and tests.
4. Avoid parallel conflicting edits. Do not merge solely because checks are green.

### C. Implement the safest useful slice
1. Add/verify failing tests for explicit route selection and product-specific route constraints.
2. Preserve clinician-entered dose/frequency/duration until a sourced protocol is approved.
3. Improve custom free-text entry and validation if still missing.
4. Ensure pharmacist queue displays the saved formulation, route and instructions using the actual existing data contract.
5. Improve structured medicine catalogue maintenance only after confirming schema, RLS, role permissions and legacy inventory compatibility.
6. Ensure first-visit weight capture uses the existing encounter-linked vitals path; do not silently reuse old weight.

### D. Keep the release gates open
- No guessed formulary rows or dosing protocols.
- No production migration or synthetic clinical/financial data.
- No declaration of clinical readiness based only on CI, PR merge or Vercel READY.
- Staff UAT, authenticated clinical E2E and relevant clinical/pharmacy review remain separate acceptance gates.

## 9. Definition of a successful continuation

The next session should start by reporting only the verified changes since this snapshot, then proceed directly with the highest-value safe implementation. The goal is a usable, reliable clinical workflow—not a growing count of phases, commits or reports.
